CDDF
Cancer Drug Development Forum

ANNUAL REPORT

2025

Cancer Drug Development Forum (CDDF)

www.cddf.org
info@cddf.org

Table of **Contents**

1.The Year in Review

2025: A Year of Evolution in Oncology Drug Development and the CDDF

Dear CDDF community,

2025 marked an inspiring new chapter for CDDF, highlighted by transitions within our management team and the appointment of new governance leaders who bring unique expertise and a refreshing perspective to our mission. As part of this evolution, we held a strategic retreat to reflect on CDDF's identity and role as a trusted convenor—one dedicated to empowering and enabling constructive dialogue among all stakeholders in oncology.

Throughout 2025, CDDF focused on keeping pace with the rapidly changing global and European landscapes for oncology drug development, ensuring that we continue to offer a neutral and timely setting for debate and discussion. In response to fast-evolving technologies and innovations in cancer research, CDDF explored key topics that are gradually shifting the paradigm. We also took an important step forward by transitioning from knowledge sharing toward knowledge generation. In particular, CDDF successfully advanced its multi-stakeholder initiative on diversity in oncology trials for Europe's population.

We are proud of the progress made amidst a shifting landscape. We emphasize the absolute requirement for continued and greater collaboration and open communication among stakeholders as an essential action to fulfil our mission—improving oncology treatments for patients.

In 2025, CDDF delivered a range of programmes focused on innovation and paradigm shifts in cancer research, innovation and care, covering topics such as AI, big data, radiopharmaceuticals, personalized vaccines, cellular therapies, Real World Evidence, innovative clinical trials, diversity in global drug development, EU Health Technology Assessment (HTA) regulation, and the Accelerating clinical trials in the EU (ACT EU).

Building on these scientific discussions and debates, CDDF continued to advance its engagement efforts. We entered Phase II of the CDDF Diversity Initiative, conducting work packages that included Multi-Stakeholder Working Group meetings on key variables. In addition, CDDF participated as an ad-hoc representative in the Multi-Stakeholder Platform Advisory Group (MSP AG) under ACT EU, contributing to ongoing European efforts to improve the clinical trials environment for patients.

1.The Year in Review

These activities are paving the way for generating tangible outcomes. CDDF continued its commitment to transforming discussions and considerations into actionable insights by publishing white papers and driving gradual, meaningful progress within the oncology community. Here are the articles we published in 2025:

- **Central and Eastern Europe: A crucible for clinical cancer innovation?** (Journal of Cancer Policy, December 2025)
- **Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action** (Cancer Treatment Reviews, November 2025)
- **Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop** (European Journal of Cancer, August 2025)

A particular highlight for me was the opportunity to conduct a fireside chat with Ms Emer Cooke, Executive Director of the European Medicines Agency (EMA) and benefit from hearing about her experiences and learnings over the last five years, in particular given the fact that she commenced her stewardship of EMA just prior to the Covid pandemic. It was a great coup for CDDF that Emer participated so fully in our Annual Conference.

Looking ahead, CDDF will continue to build on the momentum of the past year by deepening discussions on topical issues and advancements in cancer drug development, including HTA, global development strategy, patient-relevant endpoints, diversity in clinical trials, the use of big data in oncology drug development, AI in clinical research, and more. At the same time, CDDF will maintain close collaboration with its diverse range of stakeholders through multi-stakeholder discussions, EU-level initiatives, and engagement at both European and global levels via joint workshops. These efforts will be complemented by the continued translation of meeting outputs into the publication of peer review publications and white papers.

As we reflect on the past year and CDDF's achievements, we would like to extend our heartfelt thanks to all Industry Members, collaborators, and stakeholders who make CDDF's mission possible. Together, we remain committed to driving progress in oncology drug development and moving toward a future where patients benefit from timely access to innovative and effective cancer therapies.

1.The Year in Review

On a personal note and on behalf of CDDF, I would like to give my heartfelt thanks to two of the senior leaders of CDDF, Professor Jaap Verweij and Professor Ruth Plummer. Jaap and Ruth have given tireless service to CDDF in their roles as Managing Director and Chairperson respectively. Thankfully, CDDF will not lose their expertise and experience - Ruth is taking over as Managing Director and Jaap will remain on the Board of CDDF.

Professor Jaap Verweij

Professor Ruth Plummer

Prof. Mark Lawler
Chairperson of the CDDF Board of Director

2.ABOUT
THE CDDF

WHAT IS THE CDDF?

The Cancer Drug Development Forum (CDDF) is a **non-profit organisation** registered in Belgium that provides a **neutral platform** to stimulate **interaction between stakeholders** involved in cancer drug development.

CDDF'S MISSION

The CDDF's mission is to facilitate collaboration between stakeholders, to **increase efficiency** in cancer drug development and **accelerate the delivery of effective oncology treatment to patients**.

HOW DOES THE CDDF ADVANCE ITS MISSION?

To accomplish its mission, the CDDF offers **workshops**, **conferences** and **webinars** that bring together leading voices from academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers, and patient groups. By providing a **non-competitive, non-commercial platform** for multi-stakeholder discussions and collaboration, the CDDF stimulates advancement and innovation in the field through scientific debate and open discussion.

Since 2024, the CDDF has led its **Diversity Initiative**, which aims to examine key factors of inclusion in oncology clinical research. This multi-stakeholder project supports the planning and evaluation of clinical research, as well as the applicability of clinical trial outcomes to Europe's diverse population.

The CDDF also serves as an **ad hoc representative of the Multi-Stakeholder Platform Advisory Group (MSP AG)** under the Accelerating Clinical Trials in the EU (ACT EU), strengthening its engagement with stakeholders at the EU level.

3.LEADERSHIP

GOVERNANCE

CDDF Board of Directors

The CDDF is governed by a rotating board of directors dedicated to the development of cancer drug treatment. These distinguished people are experienced pre-clinical and clinical investigators, medical oncologists, regulatory scientists and statisticians representing a range of perspectives within the drug development process. In 2026, a patient advocate will be joining the Board, emphasising the CDDF's commitment to patients. The directors are elected for a period of three years.

Full and Honorary Members of Association

Full and honorary Members of the CDDF are committed to accelerating oncology drug development and delivering optimal treatment to cancer patients. Members have the right to attend General Assembly meetings, which take place once a year and are the association's sovereign authority. At these meetings, Members monitor, assess and guide CDDF's work programme, organisational directions and best practices.

17
Full/honorary Members of the association

10
CDDF Board of Directors

4
CDDF office staff members

3.LEADERSHIP

CDDF BOARD OF DIRECTORS



3.LEADERSHIP

CHANGES IN BOARD COMPOSITION

In accordance with the CDDF Articles of Association, a Member of the CDDF Board of Directors is appointed for a period of three years. The mandate of the member is renewable. This rotation policy serves to develop robust governance practices within the CDDF and encourages a dynamic and diverse composition of the Board of Directors.

During the CDDF's General Assembly in May 2025, the following leadership updates were approved:

- **Professor Mark Lawler** was appointed as new Chairperson for a three-year term, succeeding Professor Ruth Plummer. This appointment became effective as of 1 October 2025.
- **Professor Axel Glasmacher** was reappointed as Treasurer for a three-year term.
- **Professor Jaap Verweij** and **Professor Mark Lawler** were reappointed as Board Members for a three-year term.

CHANGES IN CDDF MANAGEMENT

Professor Ruth Plummer, the former Chairperson, was appointed as Managing Director, effective 1 October 2025. **Mr. Thierry Coppens** joined the CDDF as the new Director of Operations on 22 April 2025.

CONFLICTS OF INTEREST

In accordance with the Articles of Association, Board members have declared any potential conflicts of interest. The disclosure forms are provided in the appendix (page 32).

4.CDDF **OFFICE**

OFFICE STAFF MEMBERS



EMPLOYMENT DETAILS

- In 2025, with a team comprising 3.1 Full-Time Equivalent and one consultant (Managing Director), the CDDF successfully executed all planned activities and maintained seamless day-to-day operations.

5.FINANCIAL STATEMENT

REVENUE AND EXPENSES IN THE 2025 FISCAL YEAR

Total Revenue
€ 749,966.45

Total Expenses
€ 740,780.19

Balance
€ 9,186.26

TOTAL REVENUE 2025

€ 749,966.45



5.FINANCIAL STATEMENT

TOTAL EXPENSES 2025

€ 740,780.19



6.ACTIVITIES

OVERVIEW OF ACTIVITIES

In 2025, the CDDF meetings explored key innovations and the rapidly evolving landscape of cancer research, bringing together key stakeholders and experts from academia, the pharmaceutical industry, regulatory authorities, and patient advocacy groups. Leveraging the flexible webinar format, the association also provided timely discussions on the use of AI, Bayesian approaches in oncology clinical trials and the latest regulatory frameworks in Europe.

CDDF MEETINGS IN 2025

ANNUAL CONFERENCE

Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials

3 – 5 February 2025
Hybrid, Netherlands

MULTI-STAKEHOLDER WORKSHOP

New Modalities in Oncology Drug Development

31 March – 1 April 2025
Hybrid, Belgium

MULTI-STAKEHOLDER WORKSHOP

Enabling Smarter Clinical Trials to Optimise Patient Care

17 – 18 November 2025
Hybrid, Belgium

6.ACTIVITIES

OVERVIEW OF ACTIVITIES

CDDF LIVE WEBINAR SERIES

EU HTA Regulation
12 March 2025

AI and Big Data AI in Drug Development: Using AI in assessing cancer treatment response on imagine - Project Data Sphere
23 April 2025

Bayesian Framework: Bayesian Approaches in Oncology Drug Development: Introduction and Motivations
14 May 2025

AI and Big Data AI in Drug Development: Transformation of future clinical trials using AI-enhanced imaging biomarkers
18 September 2025

Long-term outcomes of in-utero exposure to cytotoxic therapy: Is involving pregnant patients an absolute no-go in cancer drug development?
4 December 2025

ACT EU: Collaborating with stakeholders to define priorities for clinical trials and working collectively to address them
15 December 2025

Recordings and slides from CDDF webinars are available to the public. Access the materials using the links above.

6.ACTIVITIES

OVERVIEW OF ACTIVITIES

CDDF PUBLICATIONS - WHITE PAPERS

Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop

European Journal of Cancer, August 2025

Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action

Cancer Treatment Reviews, November 2025

Central and Eastern Europe: A crucible for clinical cancer innovation?

Journal of Cancer Policy, December 2025

6.ACTIVITIES

OVERVIEW OF ACTIVITIES

Total number of CDDF meetings in 2025	3
Total number of CDDF webinars in 2025	6
Total number of participants	975
Participant overall satisfaction rate	4.7/5
Total number of published papers in 2025	3

Number of Participants per Meeting/Webinar



6.ACTIVITIES

Categories of Onsite Meeting Participants



This graph reflects categories of onsite meeting participants in 2025

Countries of Meeting Participants (onsite & online)



TOP 5 COUNTRIES IN EUROPE

- Switzerland (21%)
- Belgium (19%)
- United Kingdom (13%)
- Germany (9%)
- Netherlands (8%)

6.ACTIVITIES

CDDF MEETINGS IN 2025

Annual Conference: Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials

3 – 5 February 2025, hybrid, Noordwijk (Netherlands)

The Annual Conference 2025 addressed key challenges in anti-cancer drug development, focusing on diversity and inclusion in clinical trials, current and emerging oncology endpoints, innovative trial designs, diagnostic approaches, and the EU Health Technology Assessment (HTA) process. Through presentations and panel discussions, participants shared insights and experiences aimed at strengthening global cancer drug development and clinical research.

Multi-Stakeholder Workshop: New Modalities in Oncology Drug Development

31 March – 1 April 2025, hybrid, Brussels (Belgium)



The workshop brought together key stakeholders in oncology to discuss new modalities of drug development, including radiopharmaceuticals for dual diagnostic and therapeutic use, personalized cancer vaccines, next-generation targeted conjugates, and innovative approaches to previously undruggable targets. The ongoing evolution of cellular therapies, particularly CAR-T cells, was also a key topic. The interactive multi-stakeholder meeting fostered rich dialogue and collaboration to improve cancer treatments for patients.

6.ACTIVITIES

CDDF MEETINGS IN 2025

Multi-Stakeholder Workshop: Enabling Smarter Clinical Trials to Optimise Patient Care

17 – 18 November 2025, hybrid, Brussels (Belgium)

This multi-stakeholder workshop addressed how best to deploy smarter cancer clinical trials and use Real World Evidence (RWE) studies in order to deliver innovation and achieve better outcomes for cancer patients. A key emphasis throughout the workshop was "What Really Matters"—implementing proportionate, risk-based approaches in trial design and conduct. Speakers presented some of the latest studies, combined with current and future thinking on how best to define and deploy emerging evidence to ensure it becomes an integral part of how we drive innovation forward.



6.ACTIVITIES

CDDF WEBINARS IN 2025

Live Webinar: EU HTA Regulation

12 March 2025

The webinar examined the impact of the new Health Technology Assessment Regulation (HTAR), which took effect in January 2025. A panel of leading experts from the HTAR Coordination Group, the European Medicines Agency, and the industry discussed how HTAR creates new opportunities for anticancer treatments and patients amid rapid advances in oncology. Participants learned about the origins and implications of the new regulation and its significance for cancer drug development.

AI in Clinical Research: Using AI in Assessing Cancer Treatment Response on Imagine: Project Data Sphere

23 April 2025



This webinar series explores the transformative impact of artificial intelligence and big data on oncology. Featuring leading experts, it highlights the latest advances and applications of AI in cancer drug discovery, development, and regulatory science.

The second webinar highlighted that clinical validation and regulatory acceptability of AI-based methodologies are essential, particularly when used in drug development and clinical trials. Speakers also emphasized the value of pre-competitive, multi-stakeholder collaboration, noting that shared, high-quality datasets can accelerate acceptance of innovative tools and ultimately improve cancer drug development and patient care.

6.ACTIVITIES

CDDF WEBINARS IN 2025

Bayesian Framework: Bayesian Approaches in Oncology Drug Development: Introduction and Motivations

14 May 2025

As Bayesian methods become more widely used in clinical development, the CDDF webinar provided a high-level introduction to Bayesian principles, outlining both the advantages and potential limitations of the approach. The discussion highlighted that Bayesian methods offer powerful tools for clinical trial design and analysis, and that incorporating Bayesian thinking early in the planning process can significantly enhance trial efficiency and decision-making. The speakers emphasized that not considering Bayesian approaches from the start may mean missing important opportunities to improve study design and outcomes.

AI in Clinical Research: Transformation of Future Clinical Trials Using AI-Enhanced Imaging Biomarkers

18 September 2025

The webinar highlighted how advanced imaging metrics and AI can strengthen oncology clinical trials. In the first presentation, CT-based body composition measurements were introduced as emerging predictors of outcomes in solid tumors, using lung and renal cancer as examples. The second presentation demonstrated how AI can automate the detection and quantification of diverse imaging biomarkers and comorbidities on chest CT scans, improving consistency and reproducibility across trial sites. In the panel discussion, experts explored whether these body composition metrics and AI-derived biomarkers should be integrated into trial protocols.

6.ACTIVITIES

CDDF WEBINARS IN 2025

Live Webinar: Long-term outcomes of in-utero exposure to cytotoxic therapy: is involving pregnant patients an absolute no-go in cancer drug development?

4 December 2025

This webinar reviewed the ethical and scientific need to develop cancer drugs for pregnant patients to protect them and their children through cautious, prospective enrollment into clinical trials. Speakers emphasized that cancer and pregnancy often coexist and that data unique to pregnant patients cannot be obtained from other populations. The session also explored what is known about the safety of certain anticancer treatments during pregnancy and the physiological differences that affect drug behavior.

ACT EU: Collaborating with Stakeholders to Define Priorities for Clinical Trials and Working Collectively to Address Them

15 December 2025

The CDDF launched a new webinar series: Advancing Clinical Trials in the European Union (ACT EU). This series highlights collaborative efforts between regulators, industry, academia, and patient representatives to shape the future of clinical trials in Europe. The first webinar introduced the objectives of ACT EU and explained how multi-stakeholder engagement is helping to define priorities and drive meaningful change.

6.ACTIVITIES

CDDF DIVERSITY INITIATIVE

Launched in August 2024, the CDDF Diversity Initiative is a project directed by the CDDF and guided by a multi-stakeholder working group of regulators, patients, academic researchers, and pharmaceutical companies. This initiative aims to examine parameters of inclusion/diversity in clinical research, to support the planning and evaluation of clinical research, and the applicability of clinical trial outcomes to Europe's diverse population.

In 2025, the Initiative progressed into Phase II, which is structured around a series of work packages designed to deepen understanding of diversity in oncology clinical research. Five working group meetings took place throughout 2025 and one in January 2026, covering age and comorbidities, sex and gender, extrinsic and intrinsic factors, and two parts of study analysis and evaluation. The project remains on track, having successfully held its final in-person project meeting in Brussels on 5 March 2026. Phase II will conclude with the publication of a white paper in mid-2026.

PROJECT TIMELINES

- Preparation: Aug - Sep 2024
- Phase 1: Oct 2024 - Jan 2025
- Phase 2: Feb 2025 - August 2026

PHASE II PARTICIPANTS

- View the organizing committee and Phase II working group members on the CDDF website

6.ACTIVITIES

ACCELERATING CLINICAL TRIALS IN THE EU (ACT EU)



CDDF as Ad-Hoc Representative of the Multi-Stakeholder Platform Advisory Group (MSP AG)

Starting in January 2024, the Cancer Drug Development Forum has been serving as an **ad-hoc representative of the Multi-Stakeholder Platform Advisory Group (MSP AG)** within the Accelerating Clinical Trials in the EU (ACT EU) initiative. This effort, led by the European Commission, the European Medicines Agency (EMA), and the Heads of Medicines Agencies (HMA), aims to transform the EU into a region that fosters clinical trial development, collaboration, and innovation throughout the clinical research lifecycle.

To achieve this, the ACT EU's Multi-stakeholder Platform (MSP) provides a space for clinical trial stakeholders and regulators to collaborate, share perspectives, and improve the clinical trials environment for European patients. It facilitates dialogue through the MSP Advisory Group, where the CDDF participates and engages. Within this channel, the CDDF contributes to enhancing the clinical trials environment for European patients by effectively amplifying the voices of key stakeholders in oncology.

MSP ADVISORY GROUP

The MSP Advisory Group (MSP AG) is composed of representatives from key stakeholders who provide:

- Strategic advice regarding the ACT EU workplan, identifying stakeholder priorities.
- Operational advice for ACT EU initiatives, identifying experts and engagement methodology.
- Full member list available here

CDDF'S ENGAGEMENT 2025

Throughout 2025, CDDF participated in various ACT EU meetings, bringing forward multi-stakeholder perspectives gathered from CDDF discussions to the platform. Additional efforts included:

- Launching the ACT EU webinar series to inform CDDF stakeholders about ACT EU activities.
- Providing stakeholders with regular updates on ACT EU developments and opportunities for engagement.

7.COLLABORATION

Recognizing collaboration as fundamental to CDDF's mission, the association fostered and maintained cooperative relationships with diverse organizations representing key stakeholder perspectives in cancer drug development.

Accelerating Anticancer Agent Development and Validation (AAADV)

The CDDF continued its active collaboration with AAADV, exchanging best practices and key information on cancer drug development.

In 2025, a CDDF–AAADV session on global drug development was incorporated into the CDDF Annual Conference program to explore open questions related to diversity in clinical trial participation and to discuss U.S. and EU regulatory perspectives. In addition, the program for the CDDF & AAADV joint multi-stakeholder workshop on global oncology drug development, scheduled for 2026, was finalized in 2025. These collaborations provide a unique opportunity to reflect on oncology drug development beyond the European landscape and to identify challenges surrounding global development.

European Federation of Pharmaceutical Industries and Associations (EFPIA)

The CDDF maintained collaboration with the EFPIA to explore key topics, current challenges, and opportunities within oncology drug development in Europe, and to identify potential speakers for CDDF discussions.

7.COLLABORATION

European Hematology Association (EHA)

The CDDF built a collaborative relationship with the EHA through the CDDF Diversity Initiative. The EHA provided valuable insight and active engagement in the project. A subsequent management meeting further strengthened their commitment to the shared goal of improving cancer treatments for patients and to future collaborations.

European Organisation for Research and Treatment of Cancer (EORTC)

A close collaboration continued with the EORTC, along with management meetings throughout the year. As part of their collaborative efforts, the two organisations have joined forces and expertise to deliver a workshop on Health Technology Assessment in Cancer Drug Development on 5–6 October 2026 in Brussels. Denis Lacombe (EORTC) and Rosa Giuliani (CDDF) chair this multi-stakeholder meeting, which will bring together key experts and stakeholders in the field. In 2025, the programme committee was formed, and programme development actively progressed.

Friends of Cancer Research

With an effective MoU in place, the CDDF and Friends of Cancer Research continued their collaboration and maintained an open communication channel to explore collaborative opportunities and share experiences.

7.COLLABORATION

European Medicines Agency (EMA) & U.S. Food and Drug Administration (FDA)

The EMA and the FDA continued their support for CDDF multi-stakeholder discussions in 2025. Both agencies provided valuable regulatory perspective on diverse topics in cancer drug development and took part in constructive discussions with the CDDF multi-stakeholder community.

The Workgroup of European Cancer Patient Advocacy Networks (WECAN)

The WECAN and the CDDF continued to collaborate in pursuit of their common goal of enhancing cancer care for patients. WECAN representatives took part in CDDF meetings, helping ensure that patient perspectives were incorporated into discussions among various stakeholders.



8.SUSTAINABILITY

ENVIRONMENTAL RESPONSIBILITY:
CDDF's Continued Green Journey

The CDDF recognizes the importance of integrating environmental sustainability into every aspect of its organizational operations as it accomplishes its mission. The association continued to strengthen and expand its sustainability efforts by further optimizing digital event formats, reusing and repurposing materials whenever possible, and prioritizing venues and partners that demonstrate strong ecological practices. These ongoing initiatives highlight CDDF's commitment to aligning its mission in cancer research and care with responsible and sustainable operational practices.

CDDF'S SUSTAINABLE EFFORTS

- **Selecting green key venue**
- **Shared Transportation to Venue**
- **Reusing event materials** (badgets, banners, and lanyards)
- **Sustainable travel policy**
- **Reducing paper printing**
- **Reducing food waste**
- **Digitalizing** (hybrid events and digital materials)

9.ACKNOWLEDGEMENT OF **SUPPORTERS**

The CDDF thanks its members and collaborators for their engagement and invaluable contribution to support the CDDF's mission in 2025.

CDDF INDUSTRY MEMBERS IN 2025

10.CDDF IN 2026: A LOOK AHEAD



Fostering Open Discussion & Collaboration in Oncology

CDDF will continue to advance its work by deepening discussions on topical issues and advancements in cancer drug development. This includes topics such as Health Technology Assessment (HTA), global development strategies, patient-relevant endpoints, diversity in clinical trials, the use of big data in oncology R&D, the application of AI in clinical research, and additional areas central to progress in the field.

At the same time, CDDF will maintain close collaboration with its diverse range of stakeholders through multi-stakeholder discussions, EU-level initiatives, and engagement at European and global levels via joint workshops. The outcomes of these efforts will translate into publications that will help us drive gradual progress within the oncology community.

MULTI-STAKEHOLDER MEETINGS

Discussion Topics

1. **What's Hot in Global Clinical Development?**
2. **Representativeness in Global Clinical Trials**
3. **Patient Relevant Endpoints**
4. **The Use of Big Data in Oncology Drug Development**
5. **Diversity in Clinical Trials**

10.CDDF IN 2026: A LOOK AHEAD

MULTI-STAKEHOLDER MEETINGS

Discussion Topics

1. ICH E22 Guideline on Patient Preferences
2. Navigating the Regulatory Maze: Towards Global Harmonization
3. Endpoints and Patient Voice: Cornerstones of Successful Global Drug Development and Reimbursement
4. Expediting the Road to Pivotal Trials

Discussion Topics

1. Setting the Scene: HTA Landscape and Societal Needs
2. Implementation of HTA Regulation: Practical Learnings
3. HTA Regulation and Methodological Foundations
4. Looking Ahead: Preparing for Future Innovation

10.CDDF IN 2026: A LOOK AHEAD

LIVE WEBINARS

Webinars in the Planning Stage

- **AI and Big Data Series:** Transparency and risk assessment
- **CDDF Diversity Initiative paper**
- **Compassionate use / Expanded access programme in Europe**
- **Learning from "facilitating and accelerating strategic clinical trials in the EU" pilot FAST EU**



11.APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Mark Lawler

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Pfizer – Honoraria unrelated to my activities at CDDF

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

17 April 2026

Prof. Ruth Plummer

Commercial organizations with actual/potential/perceived conflicts of interest of a financial/functional/any other nature

- In the last 3 years I have received Honoraria for attending advisory boards from Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, MSD, Nerviano, Incyte, Cybrexa, Benevolent AI and Sanofi Aventis.
- I have received honoraria for working as an IDMC member for Alligator Biosciences, GSK, Onxeo, SOTIO Biotech AG, Pharmamar, and AstraZeneca.
- I have been paid for delivery of educational talks or chairing educational meetings by AstraZeneca, Novartis, Bayer, MSD and BMS.

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- My employing institution (Newcastle University) holds patents relating to rucaparib, and I have received additional income from Newcastle University under their “rewards to inventors” scheme.
- From 1st September 2025 I am under a service level agreement to work partly for NHS England as National Clinical Lead for Cancer Drugs.
- From 1st October 2025 I took up the role of Managing Director for the Cancer Drug Development Forum, (a not-for-profit organisation based in Brussels) reimbursed on an hourly consultancy rate.

20 March 2026

11.APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Stefan Symeonides

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Scientific Advisory Boards (my institution, no personal gain): Duke Street Bio, Eisai, Ellipses, Grey Wolf Therapeutics, MSD, Roche
- Independent Safety/Data Monitoring Boards (*honorarium): Exscientia/Recursion*, WCG/Valley Hospital*, University of Oxford, Institute of Cancer Research / Royal Marsden Hospital
- Speaker (honorarium): Ipsen
- Research Funding (my institution, no personal gain): MSD, Verastem
- Clinical trials as PI/CI (my institution, no personal gain): Agalimmune/BioLineRx, AZ, BioNTech, Boston Pharmaceuticals, Corbus, Genentech, Grey Wolf Therapeutics, GSK, Incyte, Medannex, MSD, Nouscom, Nucana, Nuvectis, Pfizer, Roche, Salubris, Sapience, Scancell

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- University of Edinburgh – Employment
- Cancer Research UK – Employment

28 May 2025

Prof. Axel Glasmacher

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Member of Board of Directors
  - Active Biotech AB
  - Ryvu Therapeutics S.A.
- Consultancy for pharmaceutical companies:
  - Active Biotech AB

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

19 March 2026

11.APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Dr. Catarina Edfjäll

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

20 April 2026

Dr. Rosa Giuliani

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

3 February 2024

Dr. Christian Schneider

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Working as a consultant with multiple pharmaceutical companies across all products and indications in the biopharmaceutical space.
- Salary from Cencora without any direct interest in any company

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

17 April 2026

11.APPENDIX

DISCLOSURE OF CONFLICTS OF INTEREST FOR CDDF LEADERSHIP

Prof. Eva Skovlund

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

20 March 2026

Dr. Fergus Sweeney

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Member of WHO Technical Advisory Group on Clinical Research Ecosystem Strengthening

26 March 2026

Prof. Jaap Verweij

Commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- Boehringer Ingelheim
- Deuter Oncology
- Takeda
- BionTech

Non-commercial organizations with actual/potential/perceived conflict of interest of a financial/functional/any other nature

- None

23 March 2026

Cancer Drug Development Forum (CDDF)

Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

The CDDF is a non-profit association in the register of legal entities at the French Speaking Enterprise Court in Brussels.
Enterprise number: 738.523.752

info@cddf.org
www.cddf.org
@cddf_eu
The Cancer Drug Development Forum (CDDF)